## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -5.2% below STRENGTH zone (3.0-6.0%); PEG 1.47 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-6.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($174.89)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Quest Diagnostics (NYSE: DGX) to offer Octave MSDA MS blood test at 7,000 U.S. sites**
- Source: Stock Titan | 20251201T083000 | Bullish | Relevance: 99%
- Octave Bioscience has announced a strategic collaboration with Quest Diagnostics to expand access to the Octave® Multiple Sclerosis Disease Activity (MSDA) Test across the United States. This partnership will allow patients to access the blood test at approximately 7,000 Quest Diagnostics patient access sites nationwide, making it easier for physicians to order and utilize for informed treatment decisions for MS patients. The collaboration also establishes a pathway for future novel tests from Octave's precision neurology portfolio.

**2. Quest Diagnostics Inc. stock underperforms Monday when compared to competitors**
- Source: MarketWatch | 20251201T170500 | Neutral | Relevance: 98%
-  Quest Diagnostics Inc. (DGX) stock fell 2.86% to $183.77 on Monday, underperforming the broader market. This marked the stock's third consecutive day of losses, as the S&P 500 Index (SPX) declined 0.53% and the Dow Jones Industrial Average (DJIA) fell 0.90%.

**3. Russell Investments Group Ltd. Acquires 25,768 Shares of Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251202T180729 | Bullish | Relevance: 98%
-  Russell Investments Group Ltd. increased its stake in Quest Diagnostics Incorporated (NYSE:DGX) by 40.8%, purchasing an additional 25,768 shares to reach a total of 88,848 shares valued at approximately $15.94 million. The medical research company reported strong Q2 earnings, beating analyst expectations with $2.60 EPS and $2.82 billion in revenue, and announced a quarterly dividend of $0.80 per share. Institutional investors own 88.06% of the stock, while analysts maintain a "Moderate Buy" consensus rating with a target price of $196.31.

**4. Octave Bioscience Forms Strategic Collaboration with Quest Diagnostics to Expand Patient Access to the Octave® Multiple Sclerosis Disease Activity (MSDA) Test Across the United States**
- Source: Yahoo Finance | 20251201T200828 | Bullish | Relevance: 97%
- This article from Yahoo details a strategic collaboration between Octave Bioscience and Quest Diagnostics. The partnership aims to expand patient access to Octave's Multiple Sclerosis Disease Activity (MSDA) Test throughout the United States. This will likely improve the availability of advanced diagnostic tools for managing multiple sclerosis.

**5. Quest Diagnostics Inc. stock underperforms Monday when compared to competitors**
- Source: MarketWatch | 20251201T170500 | Neutral | Relevance: 97%
-  Quest Diagnostics Inc. (DGX) stock fell 2.86% to $183.77 on Monday, experiencing its third consecutive day of losses. This underperformance occurred during a generally negative trading session, with the S&P 500 Index (SPX) down 0.53% and the Dow Jones Industrial Average (DJIA) down 0.90%.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($1.18M) |
| Sells | 8 ($8.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-6.1% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $8.9M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.47 suggests fair value with growth premium. Forward P/E 17.6x stretched relative to 6% growth. Insider selling cluster ($8.9M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.1B |
| Beta | 0.62 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.47 |
| Forward P/E | 17.6 |
| Current P/E | 18.6 |
| YoY Growth | 5.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 0.9% to -5.2% (-6.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.2pp (needs >3.0% for momentum thesis). Underperforming sector by 5.0pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.03x) but short-term weakness (below SMA20). RSI neutral at 45.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -5.19% (CS: 5) | Weak |
| RSI_14 | 44.6 | Neutral |
| MACD Histogram | -0.37 | Bearish |
| vs SMA20 | 0.984x | Below |
| vs SMA50 | 0.992x | Below |
| vs SMA200 | 1.034x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $182.55
- **Stop Loss:** $174.89 (4.2% risk)
- **Target:** $190.21 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 130
- **Position Value:** $23,731.50
- **Portfolio %:** 23.73%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*